Skip to main content
PulmovantPU

Pulmovant

Pulmovant is a clinical-stage biotechnology company dedicated to developing innovative therapies for pulmonary diseases, with its lead candidate mosliciguat being evaluated in Phase 2 clinical trials for pulmonary hypertension associated with interstitial lung disease.

About Pulmovant

We are Pulmovant, a clinical-stage biotechnology company that is singularly focused on transforming the treatment paradigm for patients with pulmonary diseases. Our first investigational product, mosliciguat, is a potential first-in-class soluble guanylate cyclase (sGC) activator designed to provide an effective, once-daily, inhaled treatment option for patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD). PH-ILD is a progressive and life-threatening condition with significant unmet medical need, and we're committed to delivering new hope for patients with these unique needs.

Our work is grounded in deep scientific understanding of the nitric oxide (NO)/cyclic guanosine monophosphate (cGMP) signaling pathway. Mosliciguat targets sGC, a key enzyme that catalyzes cGMP production, leading to increased vasodilation, reduced inflammation and apoptosis, reverse vascular remodeling, and anti-fibrotic effects. Unlike traditional sGC stimulators that require reduced heme and NO to function, our candidate is an sGC activator that works independently of these cofactors, potentially offering enhanced therapeutic benefits.

As part of the Roivant family of companies, we leverage powerful collaboration and innovation to accelerate our mission. Our Phase 2 PHocus clinical trial is evaluating the safety and efficacy of mosliciguat in adults with PH-ILD, and we've already received orphan drug designation in Japan for this potential treatment. We're driven by the belief that patients with pulmonary diseases deserve better options, and we're working every day to make that a reality.

FAQs

Is Pulmovant hiring remotely?
Yes, Pulmovant has 10 open remote jobs on Himalayas.
Which countries does Pulmovant have remote employees in?
Pulmovant has employees in United States. Check the location requirements on each of its open remote jobs.
When was Pulmovant founded?
Pulmovant was founded in 2023.
Who is the CEO of Pulmovant?
Drew Fromkin is the CEO of Pulmovant.
How many employees does Pulmovant have?
Pulmovant has 1-10 employees.
What industries or markets does Pulmovant operate in?
Pulmovant operates in the following markets: Biotech, Clinical Stage Drug Development, Inhaled Drug Delivery, Pulmonology, Pulmonary Hypertension Therapeutics, Respiratory Disease Therapeutics, Interstitial Lung Disease (ILD), Cardiopulmonary Vascular Medicine, Orphan Drug and Rare Disease Therapeutics, and Pharmaceutical.
What is Pulmovant's website?
Pulmovant's website is pulmovant.com.
Where can I find Pulmovant on social media?
You can find Pulmovant on LinkedIn.
Claim this profilePulmovant logoPU

Pulmovant

Company size

1-10 employees

Founded in

2023

Chief executive officer

Drew Fromkin

Markets

BiotechClinical Stage Drug Development
Inhaled Drug Delivery
Pulmonology
Pulmonary Hypertension Therapeutics
Respiratory Disease Therapeutics
Interstitial Lung Disease (ILD)
Cardiopulmonary Vascular Medicine
Orphan Drug and Rare Disease Therapeutics
Pharmaceutical

Employees live in

Visit pulmovant.com

10 remote jobs at Pulmovant

Explore the variety of open remote roles at Pulmovant, offering flexible work options across multiple disciplines and skill levels.

View all jobs at Pulmovant

Remote companies like Pulmovant

Find your next opportunity by exploring profiles of companies that are similar to Pulmovant. Compare culture, benefits, and job openings on Himalayas.

View all companies

Get matched with your dream remote job

Sign up now and join over 1,000,000+ remote workers who receive personalized job alerts, curated job matches, and more for free!

Sign up
Pulmovant | Himalayas